155 related articles for article (PubMed ID: 32873770)
1. Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman's Disease.
Hu C; Zou Y; Pan J; Yang J; Yang T; Tan T; Li J
Med Sci Monit; 2020 Aug; 26():e924783. PubMed ID: 32873770
[TBL] [Abstract][Full Text] [Related]
2. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman's Disease: a Retrospective Study.
Sun C; Xu G; Lin J
Clin Lab; 2018 Oct; 64(10):1671-1678. PubMed ID: 30336525
[TBL] [Abstract][Full Text] [Related]
3. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.
Sato Y; Kojima M; Takata K; Morito T; Asaoku H; Takeuchi T; Mizobuchi K; Fujihara M; Kuraoka K; Nakai T; Ichimura K; Tanaka T; Tamura M; Nishikawa Y; Yoshino T
Mod Pathol; 2009 Apr; 22(4):589-99. PubMed ID: 19270642
[TBL] [Abstract][Full Text] [Related]
4. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Features and Prognosis of Patients with Castleman's Disease].
Huang XJ; Zhang XL; Wei XF; Liang XQ; Fu Y; Zhao YY; Li QF; Zhang QK; Feng YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):135-140. PubMed ID: 36765490
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies.
Menke DM; Tiemann M; Camoriano JK; Chang SF; Madan A; Chow M; Habermann TM; Parwaresch R
Am J Clin Pathol; 1996 Mar; 105(3):268-76. PubMed ID: 8602606
[TBL] [Abstract][Full Text] [Related]
7. [Castleman disease. Histopathological and immunohistochemical analysis of 39 cases].
Sevilla-Lizcano DB; Frias-Soria CL; Ortiz-Hidalgo C
Gac Med Mex; 2017; 153(5):550-558. PubMed ID: 29099112
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of 41 cases of head and neck Castleman's disease].
Xue JF; Hao Q; Zhang YM; Cao PD; Song SP; Hu RF; Jin S
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Aug; 53(8):610-614. PubMed ID: 30122000
[No Abstract] [Full Text] [Related]
9. Primary hyaline vascular Castleman disease of the kidney: case report and literature review.
Li Y; Zhao H; Su B; Yang C; Li S; Fu W
Diagn Pathol; 2019 Aug; 14(1):94. PubMed ID: 31439011
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
11. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
Ikeda S; Chisuwa H; Kawasaki S; Ozawa J; Hoshii Y; Yokota T; Aoi T
J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
[TBL] [Abstract][Full Text] [Related]
12. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of 44 patients with head and neck Castleman's disease.
Wang T; Chen X; Chen W; Shi L; Liu J
Eur Arch Otorhinolaryngol; 2022 May; 279(5):2625-2630. PubMed ID: 34480599
[TBL] [Abstract][Full Text] [Related]
14. Castleman's disease--a two compartment model of HHV8 infection.
Schulte KM; Talat N
Nat Rev Clin Oncol; 2010 Sep; 7(9):533-43. PubMed ID: 20603649
[TBL] [Abstract][Full Text] [Related]
15. Hyaline vascular variant of unicentric Castleman disease of the tonsil: a case report.
Li P; Liu H; Li H; Li A; Yu G; Yin W
Diagn Pathol; 2019 Jun; 14(1):70. PubMed ID: 31253137
[TBL] [Abstract][Full Text] [Related]
16. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5.
Ishii T; Tatekawa T; Koseto M; Ishii M; Kobayashi H; Koike M; Fujii T; Saeki Y
Eur J Haematol; 2003 Feb; 70(2):115-8. PubMed ID: 12581193
[TBL] [Abstract][Full Text] [Related]
17. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
18. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease.
Sun PP; Yu XJ; Wang SX; Zhou XJ; Qu L; Zhang F; Ma YY; Liu G; Yang L
Nephrology (Carlton); 2020 Feb; 25(2):125-134. PubMed ID: 31264312
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.
Zhang X; Zhang P; Peng L; Fei Y; Zhang W; Feng R; Zhang W
Clin Rheumatol; 2018 Dec; 37(12):3387-3395. PubMed ID: 29948354
[TBL] [Abstract][Full Text] [Related]
20. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
Nishi J; Arimura K; Utsunomiya A; Yonezawa S; Kawakami K; Maeno N; Ijichi O; Ikarimoto N; Nakata M; Kitajima I; Fukushige T; Takamatsu H; Miyata K; Maruyama I
Br J Haematol; 1999 Mar; 104(3):482-5. PubMed ID: 10086783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
